Company
Our mission is to revolutionise drug and therapeutic discovery & development, and provide a novel and affordable solution for medical treatment, patient stratification and disease diagnostics for rare diseases of newborns.
We observed that there is a lack of effective treatment for rare diseases of newborns and there is an urgent need of human organ proxies in the dish for disease modelling, and biomarker, drug and therapeutic discovery.
To fill the gap, we will provide state-of-the-art and first-in-class human disease organoids for personalised precision medicine, regenerative medicine and preventive medicine for rare diseases of newborns. Our organoid platform marks the beginning of the deployment of a novel and affordable solution for medical treatment, patient stratification and disease diagnostics. Our platform will have a significant impact in reducing mortality rate, saving billions of dollars in healthcare costs and improving the quality of life of individuals.
Description
GLOAS (Gut Liver Organoid Advance Science) Limited – a pioneer in revolutionising drug and therapeutic discovery & development
